Humacyte Inc (NASDAQ:HUMA) shares, rose in value on Tuesday, December 31, with the stock price down by -0.79% to the previous day’s close as strong demand from buyers drove the stock to $5.05.
Actively observing the price movement in the last trading, the stock closed the session at $5.09, falling within a range of $4.86 and $5.19. The value of beta (5-year monthly) was 1.466. Referring to stock’s 52-week performance, its high was $9.97, and the low was $2.48. On the whole, HUMA has fluctuated by 11.73% over the past month.
With the market capitalization of Humacyte Inc currently standing at about $644.67 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HUMA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of HUMA currently trading nearly 13.75% and 5.23% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 56.13, while the 7-day volatility ratio is showing 10.50% which for the 30-day chart, stands at 11.81%. Furthermore, Humacyte Inc (HUMA)’s beta value is 1.33, and its average true range (ATR) is 0.56.
A comparison of Humacyte Inc (HUMA) with its peers suggests the former has fared considerably weaker in the market. HUMA showed an intraday change of -0.79% in last session, and over the past year, it grew by 77.82%%.
Data on historical trading for Humacyte Inc (NASDAQ:HUMA) indicates that the trading volumes over the past 10 days have averaged 13.49 and over the past 3 months, they’ve averaged 4.74 million. According to company’s latest data on outstanding shares, there are 119.84 million shares outstanding.
Nearly 18.88% of Humacyte Inc’s shares belong to company insiders and institutional investors own 27.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 21.96 million shares as on 2024-12-13, resulting in a short ratio of 7.53. According to the data, the short interest in Humacyte Inc (HUMA) stood at 2199.00 of shares outstanding as of 2024-12-13; the number of short shares registered in 2024-11-15 reached 19.14 million. The stock has risen by 77.82% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HUMA stock heading into the next quarter.
